ERBB2 and breast carcinoma: Furthermore, biomarker analyses from the NeoPaTHer trial may provide a better understanding of which patients are most likely to benefit from the addition of pyrotinib, paving the way for more tailored and effective treatment strategies in HER2-positive breast cancer.